

# Douglas H Thamm

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6661339/douglas-h-thamm-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

192  
papers

6,704  
citations

42  
h-index

76  
g-index

209  
ext. papers

7,721  
ext. citations

3.6  
avg, IF

5.87  
L-index

#	Paper	IF	Citations
192	Immune pathways and TP53 missense mutations are associated with longer survival in canine osteosarcoma. <i>Communications Biology</i> , <b>2021</b> , 4, 1178	6.7	0
191	Biological behaviour of primary osteosarcoma of the digits, metacarpal and metatarsal bones in dogs. <i>Veterinary and Comparative Oncology</i> , <b>2021</b> , 19, 735-742	2.5	0
190	Tumor aggressiveness is independent of radiation quality in murine hepatocellular carcinoma and mammary tumor models. <i>International Journal of Radiation Biology</i> , <b>2021</b> , 97, 1140-1151	2.9	0
189	There and back again: Translating adoptive cell therapy to canine cancer and improving human treatment. <i>Veterinary and Comparative Oncology</i> , <b>2021</b> , 19, 420-427	2.5	
188	Prospective clinical trial testing COXEN-based gene expression models of chemosensitivity in dogs with spontaneous osteosarcoma. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2021</b> , 88, 699-712	3.5	
187	Predicting likelihood of in vivo chemotherapy response in canine lymphoma using ex vivo drug sensitivity and immunophenotyping data in a machine learning model. <i>Veterinary and Comparative Oncology</i> , <b>2021</b> , 19, 160-171	2.5	2
186	Inertial focusing of circulating tumor cells in whole blood at high flow rates using the microfluidic CTCKey device for CTC enrichment. <i>Lab on A Chip</i> , <b>2021</b> , 21, 3559-3572	7.2	5
185	Canine lymphoma in 1914. <i>Veterinary and Comparative Oncology</i> , <b>2021</b> , 19, 1-2	2.5	
184	Adjuvant carboplatin for treatment of splenic hemangiosarcoma in dogs: Retrospective evaluation of 18 cases (2011-2016) and comparison with doxorubicin-based chemotherapy. <i>Journal of Veterinary Internal Medicine</i> , <b>2021</b> , 35, 1929-1934	3.1	3
183	Losartan Blocks Osteosarcoma-Elicited Monocyte Recruitment, and Combined With the Kinase Inhibitor Toceranib, Exerts Significant Clinical Benefit in Canine Metastatic Osteosarcoma. <i>Clinical Cancer Research</i> , <b>2021</b> ,	12.9	2
182	Canine Non-Angiogenic, Non-Myogenic Splenic Stromal Sarcoma: a Retrospective Clinicopathological Analysis and Investigation of Podoplanin as a Marker of Tumour Histogenesis. <i>Journal of Comparative Pathology</i> , <b>2021</b> , 188, 1-12	1	0
181	Multicenter, randomized, double-blinded, placebo-controlled study of rabacfosadine in dogs with lymphoma.. <i>Journal of Veterinary Internal Medicine</i> , <b>2021</b> ,	3.1	1
180	Phase-I trial of survivin inhibition with EZN-3042 in dogs with spontaneous lymphoma. <i>BMC Veterinary Research</i> , <b>2020</b> , 16, 97	2.7	0
179	Concurrent use of rabacfosadine and L-asparaginase for relapsed or refractory multicentric lymphoma in dogs. <i>Journal of Veterinary Internal Medicine</i> , <b>2020</b> , 34, 882-889	3.1	5
178	Rabacfosadine for naïve canine intermediate to large cell lymphoma: Efficacy and adverse event profile across three prospective clinical trials. <i>Veterinary and Comparative Oncology</i> , <b>2020</b> , 18, 763-769	2.5	5
177	Prospective evaluation of flow cytometric characteristics, histopathologic diagnosis and clinical outcome in dogs with naïve B-cell lymphoma treated with a 19-week CHOP protocol. <i>Veterinary and Comparative Oncology</i> , <b>2020</b> , 18, 342-352	2.5	10
176	Drug dose and drug choice: Optimizing medical therapy for veterinary cancer. <i>Veterinary and Comparative Oncology</i> , <b>2020</b> , 18, 143-151	2.5	3

175	Cancer of the Gastrointestinal Tract <b>2020</b> , 432-491		2
174	Phosphorylated KIT as a predictor of outcome in canine mast cell tumours treated with toceranib phosphate or vinblastine. <i>Veterinary and Comparative Oncology</i> , <b>2020</b> , 18, 169-175	2.5	7
173	Auranofin improves overall survival when combined with standard of care in a pilot study involving dogs with osteosarcoma. <i>Veterinary and Comparative Oncology</i> , <b>2020</b> , 18, 206-213	2.5	5
172	Bacterial Killing Activity of Polymorphonuclear Myeloid-Derived Suppressor Cells Isolated From Tumor-Bearing Dogs. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 2371	8.4	2
171	Prognostic significance of circulating microRNA-214 and -126 in dogs with appendicular osteosarcoma receiving amputation and chemotherapy. <i>BMC Veterinary Research</i> , <b>2019</b> , 15, 39	2.7	12
170	Novel Treatments for Lymphoma. <i>Veterinary Clinics of North America - Small Animal Practice</i> , <b>2019</b> , 49, 903-915	2.4	10
169	A temporary indwelling intravascular aphaeretic system for in vivo enrichment of circulating tumor cells. <i>Nature Communications</i> , <b>2019</b> , 10, 1478	17.4	45
168	Prognostic value of fluorine flourodeoxyglucose positron emission tomography/computed tomography in dogs with appendicular osteosarcoma. <i>Journal of Veterinary Internal Medicine</i> , <b>2019</b> , 33, 820-826	3.1	7
167	Ivermectin inhibits canine mammary tumor growth by regulating cell cycle progression and WNT signaling. <i>BMC Veterinary Research</i> , <b>2019</b> , 15, 276	2.7	11
166	Prognostic and predictive significance of KIT protein expression and c-kit gene mutation in canine cutaneous mast cell tumours: A consensus of the Oncology-Pathology Working Group. <i>Veterinary and Comparative Oncology</i> , <b>2019</b> , 17, 451-455	2.5	9
165	Canine Cancer: Strategies in Experimental Therapeutics. <i>Frontiers in Oncology</i> , <b>2019</b> , 9, 1257	5.3	13
164	Hematopoietic Tumors <b>2019</b> , 688-772		8
163	Molecular/Targeted Therapy of Cancer <b>2019</b> , 251-285		
162	Clinical Trials and Developmental Therapeutics <b>2019</b> , 340-351		
161	Mast Cell Tumors <b>2019</b> , 382-403		1
160	Miscellaneous Tumors <b>2019</b> , 773-810		1
159	Substitution of mitoxantrone for doxorubicin in a multidrug chemotherapeutic protocol for first-line treatment of dogs with multicentric intermediate- to large-cell lymphoma. <i>Journal of the American Veterinary Medical Association</i> , <b>2019</b> , 254, 236-242	1	1
158	Click Conjugation of Cloaked Peptide Ligands to Microbubbles. <i>Bioconjugate Chemistry</i> , <b>2018</b> , 29, 1534-1643		18

157	Pilot study utilizing Fluorine-18 fluorodeoxyglucose-positron emission tomography/computed tomography for glycolytic phenotyping of canine mast cell tumors. <i>Veterinary Radiology and Ultrasound</i> , <b>2018</b> , 59, 461-468	1.2	7
156	Canine sarcomas as a surrogate for the human disease. <i>Pharmacology &amp; Therapeutics</i> , <b>2018</b> , 188, 80-96	13.9	29
155	Prospective evaluation of toceranib phosphate in metastatic canine osteosarcoma. <i>Veterinary and Comparative Oncology</i> , <b>2018</b> , 16, E23-E29	2.5	19
154	Characterization of a low expression haplotype in canine glutathione S-transferase (GSTT1) and its prevalence in golden retrievers. <i>Veterinary and Comparative Oncology</i> , <b>2018</b> , 16, E61-E67	2.5	5
153	Rabacfosadine for relapsed canine B-cell lymphoma: Efficacy and adverse event profiles of 2 different doses. <i>Veterinary and Comparative Oncology</i> , <b>2018</b> , 16, E76-E82	2.5	12
152	Postsurgical Outcome in Cats with Exocrine Pancreatic Carcinoma: Nine Cases (2007-2016). <i>Journal of the American Animal Hospital Association</i> , <b>2018</b> , 54, 291-295	1.3	4
151	In vitro effects of PI3K/mTOR inhibition in canine hemangiosarcoma. <i>PLoS ONE</i> , <b>2018</b> , 13, e0200634	3.7	5
150	In vitro antineoplastic effects of auranofin in canine lymphoma cells. <i>BMC Cancer</i> , <b>2018</b> , 18, 522	4.8	4
149	Comparative oncology approach to drug repurposing in osteosarcoma. <i>PLoS ONE</i> , <b>2018</b> , 13, e0194224	3.7	14
148	c-Kit Mutation and Localization Status as Response Predictors in Mast Cell Tumors in Dogs Treated with Prednisone and Toceranib or Vinblastine. <i>Journal of Veterinary Internal Medicine</i> , <b>2018</b> , 32, 394-405	3.1	22
147	Clinical, Pathological, and Ethical Considerations for the Conduct of Clinical Trials in Dogs with Naturally Occurring Cancer: A Comparative Approach to Accelerate Translational Drug Development. <i>ILAR Journal</i> , <b>2018</b> , 59, 99-110	1.7	9
146	Somatic inactivating PTPRJ mutations and dysregulated pathways identified in canine malignant melanoma by integrated comparative genomic analysis. <i>PLoS Genetics</i> , <b>2018</b> , 14, e1007589	6	30
145	Bisphosphonate conjugation for bone specific drug targeting. <i>Bone Reports</i> , <b>2018</b> , 9, 47-60	2.6	76
144	The Flint Animal Cancer Center (FACC) Canine Tumour Cell Line Panel: a resource for veterinary drug discovery, comparative oncology and translational medicine. <i>Veterinary and Comparative Oncology</i> , <b>2017</b> , 15, 481-492	2.5	27
143	Clinical outcome of partial cystectomy for transitional cell carcinoma of the canine bladder. <i>Veterinary and Comparative Oncology</i> , <b>2017</b> , 15, 1417-1427	2.5	21
142	Expression of Phosphorylated KIT in Canine Mast Cell Tumor. <i>Veterinary Pathology</i> , <b>2017</b> , 54, 387-394	2.8	8
141	Geographical differences in survival of dogs with non-Hodgkin lymphoma treated with a CHOP based chemotherapy protocol. <i>Veterinary and Comparative Oncology</i> , <b>2017</b> , 15, 1564-1571	2.5	8
140	Alternating Rabacfosadine/Doxorubicin: Efficacy and Tolerability in Naïve Canine Multicentric Lymphoma. <i>Journal of Veterinary Internal Medicine</i> , <b>2017</b> , 31, 872-878	3.1	16

139	Canine Cutaneous Plasmacytosis: 21 Cases (2005-2015). <i>Journal of Veterinary Internal Medicine</i> , <b>2017</b> , 31, 1074-1080	3.1	12
138	<i>Proteus mirabilis</i> inhibits cancer growth and pulmonary metastasis in a mouse breast cancer model. <i>PLoS ONE</i> , <b>2017</b> , 12, e0188960	3.7	9
137	Epithelial Cell Adhesion Molecule Expression in Canine Tumours. <i>Journal of Comparative Pathology</i> , <b>2016</b> , 155, 299-304	1	4
136	Relative biological effectiveness in canine osteosarcoma cells irradiated with accelerated charged particles. <i>Oncology Letters</i> , <b>2016</b> , 12, 1597-1601	2.6	5
135	Perspectives from man's best friend: National Academy of Medicine's Workshop on Comparative Oncology. <i>Science Translational Medicine</i> , <b>2016</b> , 8, 324ps5	17.5	85
134	Intrinsic Radiosensitivity and Cellular Characterization of 27 Canine Cancer Cell Lines. <i>PLoS ONE</i> , <b>2016</b> , 11, e0156689	3.7	16
133	Survivin inhibition via EZN-3042 in canine lymphoma and osteosarcoma. <i>Veterinary and Comparative Oncology</i> , <b>2016</b> , 14, e45-57	2.5	6
132	Retrospective analysis for treatment of naïve canine multicentric lymphoma with a 15-week, maintenance-free CHOP protocol. <i>Veterinary and Comparative Oncology</i> , <b>2016</b> , 14 Suppl 1, 147-55	2.5	35
131	Changes in cell shape are correlated with metastatic potential in murine and human osteosarcomas. <i>Biology Open</i> , <b>2016</b> , 5, 289-99	2.2	38
130	Serum 25-hydroxyvitamin D concentrations in dogs - correlation with health and cancer risk. <i>Veterinary and Comparative Oncology</i> , <b>2016</b> , 14, 295-305	2.5	42
129	The effect of Zhangfei/CREBZF on cell growth, differentiation, apoptosis, migration, and the unfolded protein response in several canine osteosarcoma cell lines. <i>BMC Veterinary Research</i> , <b>2015</b> , 11, 22	2.7	11
128	What Is Your Diagnosis? Renal adenocarcinoma. <i>Journal of the American Veterinary Medical Association</i> , <b>2015</b> , 247, 247-9	1	
127	Maintenance therapy with toceranib following doxorubicin-based chemotherapy for canine splenic hemangiosarcoma. <i>BMC Veterinary Research</i> , <b>2015</b> , 11, 131	2.7	26
126	Novel acyclic nucleotide analogues GS-343074 and GS-424044 demonstrate antiproliferative and pro-apoptotic activity in canine neoplastic cell lines. <i>Veterinary and Comparative Oncology</i> , <b>2015</b> , 13, 246-34	2.5	5
125	Pulse-Administered Toceranib Phosphate Plus Lomustine for Treatment of Unresectable Mast Cell Tumors in Dogs. <i>Journal of Veterinary Internal Medicine</i> , <b>2015</b> , 29, 1098-104	3.1	14
124	Vinorelbine rescue therapy for dogs with primary urinary bladder carcinoma. <i>Veterinary and Comparative Oncology</i> , <b>2015</b> , 13, 443-51	2.5	4
123	Response evaluation criteria for solid tumours in dogs (v1.0): a Veterinary Cooperative Oncology Group (VCOG) consensus document. <i>Veterinary and Comparative Oncology</i> , <b>2015</b> , 13, 176-83	2.5	206
122	Impact of Toceranib/Piroxicam/Cyclophosphamide Maintenance Therapy on Outcome of Dogs with Appendicular Osteosarcoma following Amputation and Carboplatin Chemotherapy: A Multi-Institutional Study. <i>PLoS ONE</i> , <b>2015</b> , 10, e0124889	3.7	43

121	Veterinary oncology clinical trials: design and implementation. <i>Veterinary Journal</i> , <b>2015</b> , 205, 226-32	2.5	11
120	Comparative pharmacokinetic properties and antitumor activity of the marine HDACi Largazole and Largazole peptide isostere. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2015</b> , 75, 671-82	3.5	19
119	Development of Masitinib for the Treatment of Peripheral T-Cell Lymphoma. <i>Blood</i> , <b>2015</b> , 126, 3993-3998		
118	GS-9219/VDC-1101--a prodrug of the acyclic nucleotide PMEG has antitumor activity in spontaneous canine multiple myeloma. <i>BMC Veterinary Research</i> , <b>2014</b> , 10, 30	2.7	12
117	Comparison of carboplatin and doxorubicin-based chemotherapy protocols in 470 dogs after amputation for treatment of appendicular osteosarcoma. <i>Journal of Veterinary Internal Medicine</i> , <b>2014</b> , 28, 554-63	3.1	91
116	Phase II evaluation of VDC-1101 in canine cutaneous T-cell lymphoma. <i>Journal of Veterinary Internal Medicine</i> , <b>2014</b> , 28, 1569-74	3.1	20
115	Malignant mesenchymoma with widespread metastasis including bone marrow involvement in a dog. <i>Veterinary Clinical Pathology</i> , <b>2014</b> , 43, 447-52	1	4
114	Autophagy and cancer therapy. <i>Molecular Pharmacology</i> , <b>2014</b> , 85, 830-8	4.3	225
113	The immunosignature of canine lymphoma: characterization and diagnostic application. <i>BMC Cancer</i> , <b>2014</b> , 14, 657	4.8	8
112	Development of an in vitro model of acquired resistance to toceranib phosphate (Palladia <sup>®</sup> ) in canine mast cell tumor. <i>BMC Veterinary Research</i> , <b>2014</b> , 10, 105	2.7	20
111	Correlation of nodal mast cells with clinical outcome in dogs with mast cell tumour and a proposed classification system for the evaluation of node metastasis. <i>Journal of Comparative Pathology</i> , <b>2014</b> , 151, 329-38	1	59
110	Phase I clinical trial and pharmacodynamic evaluation of combination hydroxychloroquine and doxorubicin treatment in pet dogs treated for spontaneously occurring lymphoma. <i>Autophagy</i> , <b>2014</b> , 10, 1415-25	10.2	124
109	Diagnostic accuracy of pre-treatment biopsy for grading soft tissue sarcomas in dogs. <i>Veterinary and Comparative Oncology</i> , <b>2014</b> , 12, 106-13	2.5	11
108	Development of a limited-sampling model for prediction of doxorubicin exposure in dogs. <i>Veterinary and Comparative Oncology</i> , <b>2014</b> , 12, 114-9	2.5	5
107	HES1, a target of Notch signaling, is elevated in canine osteosarcoma, but reduced in the most aggressive tumors. <i>BMC Veterinary Research</i> , <b>2013</b> , 9, 130	2.7	30
106	Disease distribution in canine patients with acanthocytosis: 123 cases. <i>Veterinary Clinical Pathology</i> , <b>2013</b> , 42, 465-70	1	11
105	Retrospective evaluation of doxorubicin-piroxicam combination for the treatment of transitional cell carcinoma in dogs. <i>Journal of Small Animal Practice</i> , <b>2013</b> , 54, 67-74	1.6	25
104	Evaluation of a 15-week CHOP protocol for the treatment of canine multicentric lymphoma. <i>Veterinary and Comparative Oncology</i> , <b>2013</b> , 11, 306-15	2.5	36

103	Mast Cell Tumors <b>2013</b> , 335-355		40
102	DNA repair deficiency as a susceptibility marker for spontaneous lymphoma in golden retriever dogs: a case-control study. <i>PLoS ONE</i> , <b>2013</b> , 8, e69192	3.7	7
101	Clinical and immunomodulatory effects of toceranib combined with low-dose cyclophosphamide in dogs with cancer. <i>Journal of Veterinary Internal Medicine</i> , <b>2012</b> , 26, 355-62	3.1	69
100	A randomized trial investigating the efficacy and safety of water soluble micellar paclitaxel (Paccal Vet) for treatment of nonresectable grade 2 or 3 mast cell tumors in dogs. <i>Journal of Veterinary Internal Medicine</i> , <b>2012</b> , 26, 598-607	3.1	31
99	Masitinib as a chemosensitizer of canine tumor cell lines: a proof of concept study. <i>Veterinary Journal</i> , <b>2012</b> , 191, 131-4	2.5	20
98	A systems biology approach to identify molecular pathways altered by HDAC inhibition in osteosarcoma. <i>Journal of Cellular Biochemistry</i> , <b>2012</b> , 113, 773-83	4.7	18
97	Multicenter prospective trial of hypofractionated radiation treatment, toceranib, and prednisone for measurable canine mast cell tumors. <i>Journal of Veterinary Internal Medicine</i> , <b>2012</b> , 26, 135-41	3.1	36
96	Preliminary evidence for biologic activity of toceranib phosphate (Palladia(®)) in solid tumours. <i>Veterinary and Comparative Oncology</i> , <b>2012</b> , 10, 194-205	2.5	136
95	Phase II clinical evaluation of lomustine chemotherapy for feline vaccine-associated sarcoma. <i>Veterinary and Comparative Oncology</i> , <b>2012</b> , 10, 283-91	2.5	15
94	Elevated serum thymidine kinase activity in canine splenic hemangiosarcoma*. <i>Veterinary and Comparative Oncology</i> , <b>2012</b> , 10, 292-302	2.5	19
93	An asymmetric synthesis of 1,2,4-trioxane anticancer agents via desymmetrization of peroxyquinols through a Brønsted acid catalysis cascade. <i>Journal of the American Chemical Society</i> , <b>2012</b> , 134, 13554-7	16.4	174
92	What is your diagnosis? Extraskelatal osteosarcoma. <i>Journal of the American Veterinary Medical Association</i> , <b>2012</b> , 240, 265-6	1	
91	Preclinical evaluation of oncolytic vaccinia virus for therapy of canine soft tissue sarcoma. <i>PLoS ONE</i> , <b>2012</b> , 7, e37239	3.7	37
90	Expression and function of survivin in canine osteosarcoma. <i>Cancer Research</i> , <b>2012</b> , 72, 249-59	10.1	41
89	Immunohistochemical characterization of feline oral squamous cell carcinoma. <i>American Journal of Veterinary Research</i> , <b>2012</b> , 73, 1801-6	1.1	19
88	Genomic instability and telomere fusion of canine osteosarcoma cells. <i>PLoS ONE</i> , <b>2012</b> , 7, e43355	3.7	25
87	Abstract A56: Canine Mast Cell Tumor and Toceranib Phosphate (Palladia®) Development of a Spontaneous Canine Model of Kinase Inhibitor Resistance. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, A56-A56	12.9	
86	Spontaneous Companion Animal (Pet) Cancers <b>2011</b> , 353-373		2

85	Low-dose cyclophosphamide selectively decreases regulatory T cells and inhibits angiogenesis in dogs with soft tissue sarcoma. <i>Journal of Veterinary Internal Medicine</i> , <b>2011</b> , 25, 920-6	3.1	82
84	Increased monocyte chemotactic protein-1 concentration and monocyte count independently associate with a poor prognosis in dogs with lymphoma. <i>Veterinary and Comparative Oncology</i> , <b>2011</b> , 9, 55-64	2.5	45
83	Induction of VEGF by tepoxalin does not lead to increased tumour growth in a canine osteosarcoma xenograft. <i>Veterinary and Comparative Oncology</i> , <b>2011</b> , 9, 118-30	2.5	6
82	Epidermal growth factor enhances the malignant phenotype in canine mammary carcinoma cell lines. <i>Veterinary and Comparative Oncology</i> , <b>2011</b> , 9, 196-206	2.5	11
81	Optofluidic intracavity spectroscopy of canine hemangiosarcoma. <i>IEEE Transactions on Biomedical Engineering</i> , <b>2011</b> , 58, 853-60	5	8
80	Glycolysis inhibition by 2-deoxy-D-glucose reverts the metastatic phenotype in vitro and in vivo. <i>Clinical and Experimental Metastasis</i> , <b>2011</b> , 28, 865-75	4.7	70
79	The histone deacetylase inhibitor valproic acid sensitizes human and canine osteosarcoma to doxorubicin. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2011</b> , 67, 83-92	3.5	50
78	Diagnosis and management of lymphoma in a green iguana ( <i>Iguana iguana</i> ). <i>Journal of the American Veterinary Medical Association</i> , <b>2011</b> , 239, 985-91	1	21
77	Recommended guidelines for the conduct and evaluation of prognostic studies in veterinary oncology. <i>Veterinary Pathology</i> , <b>2011</b> , 48, 7-18	2.8	61
76	Interleukin-11 receptor alpha is expressed on canine osteosarcoma. <i>Veterinary and Comparative Oncology</i> , <b>2010</b> , 8, 96-102	2.5	5
75	Doxorubicin and cyclophosphamide for the treatment of canine lymphoma: a randomized, placebo-controlled study. <i>Veterinary and Comparative Oncology</i> , <b>2010</b> , 8, 188-95	2.5	24
74	Preclinical investigation of PEGylated tumor necrosis factor alpha in dogs with spontaneous tumors: phase I evaluation. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 1498-508	12.9	31
73	The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2010</b> , 107, 13075-80	11.5	1095
72	Lung tumor development and spontaneous regression in lambs coinfecting with Jaagsiekte sheep retrovirus and ovine lentivirus. <i>Veterinary Pathology</i> , <b>2010</b> , 47, 148-62	2.8	18
71	Phase I pharmacokinetic and pharmacodynamic evaluation of combined valproic acid/doxorubicin treatment in dogs with spontaneous cancer. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 4832-42	12.9	24
70	Pharmacokinetic modeling of doxorubicin pharmacokinetics in dogs deficient in ABCB1 drug transporters. <i>Journal of Veterinary Internal Medicine</i> , <b>2010</b> , 24, 579-86	3.1	15
69	Improving reporting of clinical trials in veterinary medicine. <i>Journal of Veterinary Internal Medicine</i> , <b>2010</b> , 24, 799-800; author reply 801-2	3.1	3
68	Association of blood monocyte and lymphocyte count and disease-free interval in dogs with osteosarcoma. <i>Journal of Veterinary Internal Medicine</i> , <b>2010</b> , 24, 1439-44	3.1	45



67	RT-PCR-based tyrosine kinase display profiling of canine melanoma: IGF-1 receptor as a potential therapeutic target. <i>Melanoma Research</i> , <b>2010</b> , 20, 35-42	3.3	11
66	Transverse mode analysis of optofluidic intracavity spectroscopy of canine hemangiosarcoma <b>2010</b> ,		1
65	Multiple distinct malignancies in dogs: 53 cases. <i>Journal of the American Animal Hospital Association</i> , <b>2010</b> , 46, 20-30	1.3	21
64	Surface Modification of Positive Contrast Nanoparticle Agents with RAFT Polymers Towards the Targeted Imaging and Treatment of Cancer. <i>ACS Symposium Series</i> , <b>2010</b> , 65-101	0.4	2
63	Chronic bacterial osteomyelitis suppression of tumor growth requires innate immune responses. <i>Cancer Immunology, Immunotherapy</i> , <b>2010</b> , 59, 367-78	7.4	38
62	An orthotopic, postsurgical model of luciferase transfected murine osteosarcoma with spontaneous metastasis. <i>Clinical and Experimental Metastasis</i> , <b>2010</b> , 27, 151-60	4.7	19
61	The creation of the Comparative Oncology Trials Consortium Pharmacodynamic Core: Infrastructure for a virtual laboratory. <i>Veterinary Journal</i> , <b>2010</b> , 185, 88-9	2.5	9
60	Assessment of GS-9219 in a pet dog model of non-Hodgkin's lymphoma. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 3503-10	12.9	49
59	Comparison of fluid types for resuscitation after acute blood loss in mallard ducks ( <i>Anas platyrhynchos</i> ). <i>Journal of Veterinary Emergency and Critical Care</i> , <b>2009</b> , 19, 467-72	1.7	12
58	Tuning the magnetic resonance imaging properties of positive contrast agent nanoparticles by surface modification with RAFT polymers. <i>Langmuir</i> , <b>2009</b> , 25, 9487-99	4	106
57	Polymer-modified gadolinium metal-organic framework nanoparticles used as multifunctional nanomedicines for the targeted imaging and treatment of cancer. <i>Biomacromolecules</i> , <b>2009</b> , 10, 983-93	6.9	232
56	Combination chemotherapy with continuous L-asparaginase, lomustine, and prednisone for relapsed canine lymphoma. <i>Journal of Veterinary Internal Medicine</i> , <b>2009</b> , 23, 1058-63	3.1	36
55	Launching a novel preclinical infrastructure: comparative oncology trials consortium directed therapeutic targeting of TNFalpha to cancer vasculature. <i>PLoS ONE</i> , <b>2009</b> , 4, e4972	3.7	93
54	NOD/SCID mouse model of canine T-cell lymphoma with humoral hypercalcaemia of malignancy: cytokine gene expression profiling and in vivo bioluminescent imaging. <i>Veterinary and Comparative Oncology</i> , <b>2008</b> , 6, 39-54	2.5	13
53	Dose-escalating vinblastine for the treatment of canine mast cell tumour. <i>Veterinary and Comparative Oncology</i> , <b>2008</b> , 6, 111-9	2.5	20
52	Serum vascular endothelial growth factor concentrations and postsurgical outcome in dogs with osteosarcoma. <i>Veterinary and Comparative Oncology</i> , <b>2008</b> , 6, 126-32	2.5	29
51	Glucose transporter 1 expression in canine osteosarcoma. <i>Veterinary and Comparative Oncology</i> , <b>2008</b> , 6, 133-40	2.5	12
50	Systems biology approach to identification of biomarkers for metastatic progression in cancer. <i>BMC Bioinformatics</i> , <b>2008</b> , 9 Suppl 9, S8	3.6	33

49	Comparative analysis of survivin expression in untreated and relapsed canine lymphoma. <i>Journal of Veterinary Internal Medicine</i> , <b>2008</b> , 22, 989-95	3.1	25
48	Impact of telomerase status on canine osteosarcoma patients. <i>Journal of Veterinary Internal Medicine</i> , <b>2008</b> , 22, 1366-72	3.1	12
47	Cyclooxygenase-2 expression in equine tumors. <i>Veterinary Pathology</i> , <b>2008</b> , 45, 825-8	2.8	16
46	GS-9219--a novel acyclic nucleotide analogue with potent antineoplastic activity in dogs with spontaneous non-Hodgkin's lymphoma. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 2824-32	12.9	67
45	Four-fraction radiation therapy for macroscopic soft tissue sarcomas in 16 dogs. <i>Journal of the American Animal Hospital Association</i> , <b>2008</b> , 44, 100-8	1.3	23
44	Evaluation of prognostic markers for canine mast cell tumors treated with vinblastine and prednisone. <i>BMC Veterinary Research</i> , <b>2008</b> , 4, 32	2.7	43
43	Serum concentrations of cardiac troponin I and cardiac troponin T in dogs with class IV congestive heart failure due to mitral valve disease. <i>Journal of Veterinary Emergency and Critical Care</i> , <b>2007</b> , 17, 243-249	1.7	16
42	Human granulocyte-macrophage colony-stimulating factor DNA cationic-lipid complexed autologous tumour cell vaccination in the treatment of canine B-cell multicentric lymphoma. <i>Veterinary and Comparative Oncology</i> , <b>2007</b> , 5, 219-31	2.5	25
41	Evaluation of a xenogeneic VEGF vaccine in dogs with soft tissue sarcoma. <i>Cancer Immunology, Immunotherapy</i> , <b>2007</b> , 56, 1299-309	7.4	45
40	Aftershocks of cancer chemotherapy: managing adverse effects. <i>Journal of the American Animal Hospital Association</i> , <b>2007</b> , 43, 1-7	1.3	17
39	Successful Treatment of Acute Tumor Lysis Syndrome in a Dog with Multicentric Lymphoma. <i>Journal of Veterinary Internal Medicine</i> , <b>2007</b> , 21, 1401-1404	3.1	17
38	Evaluation of a Novel Tumor Vaccine in Dogs with Hemangiosarcoma. <i>Journal of Veterinary Internal Medicine</i> , <b>2007</b> , 21, 113-120	3.1	55
37	Combination Chemotherapy with L-Asparaginase, Lomustine, and Prednisone for Relapsed or Refractory Canine Lymphoma. <i>Journal of Veterinary Internal Medicine</i> , <b>2007</b> , 21, 127-132	3.1	45
36	Combination chemotherapy with L-asparaginase, lomustine, and prednisone for relapsed or refractory canine lymphoma. <i>Journal of Veterinary Internal Medicine</i> , <b>2007</b> , 21, 127-32	3.1	12
35	Evaluation of a novel tumor vaccine in dogs with hemangiosarcoma. <i>Journal of Veterinary Internal Medicine</i> , <b>2007</b> , 21, 113-20	3.1	21
34	GS-9219 - A Novel Prodrug of the Acyclic Nucleotide PMEG Demonstrates Significant Therapeutic Activity Against Spontaneous Non-Hodgkin's Lymphoma as Modeled in Pet Dogs.. <i>Blood</i> , <b>2007</b> , 110, 1380-1380	2.2	23
33	GS-9219 - A Novel Prodrug of the Acyclic Nucleotide PMEG Has Antitumor Activity Against Naive and Melphalan-Refractory Spontaneous Myeloma in Pet Dogs.. <i>Blood</i> , <b>2007</b> , 110, 1508-1508	2.2	23
32	Mast Cell Tumors <b>2007</b> , 402-424		59

31	Successful treatment of acute tumor lysis syndrome in a dog with multicentric lymphoma. <i>Journal of Veterinary Internal Medicine</i> , <b>2007</b> , 21, 1401-4	3.1	3
30	Evaluation of prognostic factors associated with outcome in dogs with multiple cutaneous mast cell tumors treated with surgery with and without adjuvant treatment: 54 cases (1998-2004). <i>Journal of the American Veterinary Medical Association</i> , <b>2006</b> , 228, 91-5	1	65
29	Biological and molecular characterization of a canine hemangiosarcoma-derived cell line. <i>Research in Veterinary Science</i> , <b>2006</b> , 81, 76-86	2.5	37
28	Outcome and prognostic factors following adjuvant prednisone/vinblastine chemotherapy for high-risk canine mast cell tumour: 61 cases. <i>Journal of Veterinary Medical Science</i> , <b>2006</b> , 68, 581-7	1.1	97
27	Interactions between radiation therapy and immunotherapy: the best of two worlds?. <i>Veterinary and Comparative Oncology</i> , <b>2006</b> , 4, 189-97	2.5	9
26	Plasma synthesis of carbon-iron magnetic nanoparticles and immobilization of doxorubicin for targeted drug delivery. <i>Journal of Materials Engineering and Performance</i> , <b>2006</b> , 15, 376-382	1.6	6
25	Does l-Asparaginase Influence Efficacy or Toxicity When Added to a Standard CHOP Protocol for Dogs with Lymphoma?. <i>Journal of Veterinary Internal Medicine</i> , <b>2005</b> , 19, 732-736	3.1	69
24	Cytotoxic chemotherapy: new players, new tactics. <i>Journal of the American Animal Hospital Association</i> , <b>2005</b> , 41, 209-14	1.3	1
23	Systemic administration of an attenuated, tumor-targeting <i>Salmonella typhimurium</i> to dogs with spontaneous neoplasia: phase I evaluation. <i>Clinical Cancer Research</i> , <b>2005</b> , 11, 4827-34	12.9	115
22	Does L-asparaginase influence efficacy or toxicity when added to a standard CHOP protocol for dogs with lymphoma?. <i>Journal of Veterinary Internal Medicine</i> , <b>2005</b> , 19, 732-6	3.1	22
21	Plasma synthesis of carbon magnetic nanoparticles and immobilization of doxorubicin for targeted drug delivery. <i>Journal of Biomaterials Science, Polymer Edition</i> , <b>2004</b> , 15, 1033-49	3.5	23
20	Imatinib mesylate inhibits platelet-derived growth factor activity and increases chemosensitivity in feline vaccine-associated sarcoma. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2004</b> , 54, 25-33	3.5	69
19	IGF-1 receptor contributes to the malignant phenotype in human and canine osteosarcoma. <i>Journal of Cellular Biochemistry</i> , <b>2004</b> , 92, 77-91	4.7	105
18	Spontaneously Occurring Tumors in Companion Animals as Models for Drug Development <b>2004</b> , 259-284		16
17	c-Met tyrosine kinase receptor expression and function in human and canine osteosarcoma cells. <i>Clinical and Experimental Metastasis</i> , <b>2003</b> , 20, 421-30	4.7	56
16	Intralesional lipid-complexed cytokine/superantigen immunogene therapy for spontaneous canine tumors. <i>Cancer Immunology, Immunotherapy</i> , <b>2003</b> , 52, 473-80	7.4	22
15	Carcinoma of the apocrine glands of the anal sac in dogs: 113 cases (1985-1995). <i>Journal of the American Veterinary Medical Association</i> , <b>2003</b> , 223, 825-31	1	94
14	Preclinical study of dolastatin-10 in dogs with spontaneous neoplasia. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2002</b> , 49, 251-5	3.5	12

13	Evaluation of a 6-Month Chemotherapy Protocol with No Maintenance Therapy for Dogs with Lymphoma. <i>Journal of Veterinary Internal Medicine</i> , <b>2002</b> , 16, 704-709	3.1	216
12	Liposome-Encapsulated Doxorubicin (Doxil) and Doxorubicin in the Treatment of Vaccine-Associated Sarcoma in Cats. <i>Journal of Veterinary Internal Medicine</i> , <b>2002</b> , 16, 726-731	3.1	73
11	Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma. <i>Journal of Veterinary Internal Medicine</i> , <b>2002</b> , 16, 704-9	3.1	78
10	Liposome-encapsulated doxorubicin (Doxil) and doxorubicin in the treatment of vaccine-associated sarcoma in cats. <i>Journal of Veterinary Internal Medicine</i> , <b>2002</b> , 16, 726-31	3.1	12
9	Primary osteosarcoma of the synovium in a dog. <i>Journal of the American Animal Hospital Association</i> , <b>2000</b> , 36, 326-31	1.3	10
8	What is your diagnosis? A soft-tissue mass in the thoracic cavity between the heart and the right crus of the diaphragm. <i>Journal of the American Veterinary Medical Association</i> , <b>2000</b> , 216, 23-4	1	4
7	Prednisone and Vinblastine Chemotherapy for Canine Mast Cell Tumor--41 Cases (1992-1997). <i>Journal of Veterinary Internal Medicine</i> , <b>1999</b> , 13, 491-497	3.1	90
6	Prednisone and vinblastine chemotherapy for canine mast cell tumor--41 cases (1992-1997). <i>Journal of Veterinary Internal Medicine</i> , <b>1999</b> , 13, 491-7	3.1	86
5	Possible cardiotoxicity associated with low-dose doxorubicin during chemotherapy in a ring-tailed lemur ( <i>Lemur catta</i> ) with multicentric lymphoma. <i>Veterinary Record Case Reports</i> ,	0.2	
4	Assessment of the Chemotherapy Patient37-56		
3	Chemotherapy Agents93-99		
2	Management of Chemotherapy Side Effects101-112		
1	Dispelling the Myths of Animal Cancer and Its Treatment1-14		